MMF induction is a viable alternative to cyclophosphamide for treating mixed proliferative lupus nephritis in children. Oral mycophenolate mofetil (MMF) is as effective as intravenous cyclophosphamide ...

In children with lupus nephritis, neurological manifestations at the time of kidney biopsy, age, and eGFR predicted greater risk of CKD progression. Investigators have identified predictors of chronic ...

With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. GSK plc (LSE/NYSE: GSK) today ...

The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, ...

Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.

Investing.com -- The U.S. Food and Drug Administration (FDA) has approved Roche Holding AG’s (SIX:RO) Gazyva/Gazyvaro ...

The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...

Basel: Roche has announced that the US Food and Drug Administration (FDA) has approved Gazyva/Gazyvaro (obinutuzumab) for the ...

Positive recommendation based on phase II NOBILITY and phase III REGENCY data showing Gazyva/Gazyvaro’s superiority over ...

FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data –– Gazyva is the only anti-CD20 monoclonal antibody to demonstrate a ...